252 related articles for article (PubMed ID: 36270724)
1. Hepatocellular Carcinoma in Primary Biliary Cholangitis.
Sy AM; Ferreira RD; John BV
Clin Liver Dis; 2022 Nov; 26(4):691-704. PubMed ID: 36270724
[TBL] [Abstract][Full Text] [Related]
2. Ursodeoxycholic Acid Response Is Associated With Reduced Mortality in Primary Biliary Cholangitis With Compensated Cirrhosis.
John BV; Khakoo NS; Schwartz KB; Aitchenson G; Levy C; Dahman B; Deng Y; Goldberg DS; Martin P; Kaplan DE; Taddei TH
Am J Gastroenterol; 2021 Sep; 116(9):1913-1923. PubMed ID: 33989225
[TBL] [Abstract][Full Text] [Related]
3. Incidence of Hepatocellular Carcinoma in Primary Biliary Cholangitis: A Systematic Review and Meta-Analysis.
Natarajan Y; Tansel A; Patel P; Emologu K; Shukla R; Qureshi Z; El-Serag HB; Thrift AP; Kanwal F
Dig Dis Sci; 2021 Jul; 66(7):2439-2451. PubMed ID: 32743773
[TBL] [Abstract][Full Text] [Related]
4. Relatively high risk for hepatocellular carcinoma in patients with primary biliary cirrhosis not responding to ursodeoxycholic acid.
Kuiper EM; Hansen BE; Adang RP; van Nieuwkerk CM; Timmer R; Drenth JP; Spoelstra P; Brouwer HT; Kuyvenhoven JP; van Buuren HR;
Eur J Gastroenterol Hepatol; 2010 Dec; 22(12):1495-502. PubMed ID: 21389798
[TBL] [Abstract][Full Text] [Related]
5. Toward precision medicine in primary biliary cholangitis.
Carbone M; Ronca V; Bruno S; Invernizzi P; Mells GF
Dig Liver Dis; 2016 Aug; 48(8):843-50. PubMed ID: 27324985
[TBL] [Abstract][Full Text] [Related]
6. [Research progress on risk factors for poor response of ursodeoxycholic acid in primary biliary cholangitis].
Yuan Z; Jia G; Han Y
Zhonghua Gan Zang Bing Za Zhi; 2019 Jan; 27(1):73-76. PubMed ID: 30685931
[TBL] [Abstract][Full Text] [Related]
7. Obeticholic acid for the treatment of primary biliary cholangitis.
Ali AH; Lindor KD
Expert Opin Pharmacother; 2016 Sep; 17(13):1809-15. PubMed ID: 27468093
[TBL] [Abstract][Full Text] [Related]
8. Decreased infiltration of CD4
Yu K; Li P; Xu T; Xu J; Wang K; Chai J; Zhao D; Liu Y; Wang Y; Ma J; Fan L; Guo S; Li Z; Li M; Wang Z
Pathol Res Pract; 2021 Jan; 217():153291. PubMed ID: 33249399
[TBL] [Abstract][Full Text] [Related]
9. Seladelpar in patients with primary biliary cholangitis: Need for a closer look!
Mishra AK; Singh SP
J Hepatol; 2022 Nov; 77(5):1451. PubMed ID: 35594993
[No Abstract] [Full Text] [Related]
10. [Diagnosis and Treatment of Primary Biliary Cholangitis].
Kim KA
Korean J Gastroenterol; 2023 Feb; 81(2):86-90. PubMed ID: 36824036
[TBL] [Abstract][Full Text] [Related]
11. Latest and emerging therapies for primary biliary cirrhosis and primary sclerosing cholangitis.
Zein CO; Lindor KD
Curr Gastroenterol Rep; 2010 Feb; 12(1):13-22. PubMed ID: 20425480
[TBL] [Abstract][Full Text] [Related]
12. Epidemiology and clinical course of primary biliary cholangitis in Eastern Slovakia.
Drazilova S; Babinska I; Gazda J; Halanova M; Janicko M; Kucinsky B; Safcak D; Martinkova D; Tarbajova L; Cekanova A; Jarcuska P;
Int J Public Health; 2020 Jun; 65(5):683-691. PubMed ID: 32500239
[TBL] [Abstract][Full Text] [Related]
13. Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis.
Harms MH; van Buuren HR; Corpechot C; Thorburn D; Janssen HLA; Lindor KD; Hirschfield GM; Parés A; Floreani A; Mayo MJ; Invernizzi P; Battezzati PM; Nevens F; Ponsioen CY; Mason AL; Kowdley KV; Lammers WJ; Hansen BE; van der Meer AJ
J Hepatol; 2019 Aug; 71(2):357-365. PubMed ID: 30980847
[TBL] [Abstract][Full Text] [Related]
14. Worse Response to Ursodeoxycholic Acid in Primary Biliary Cholangitis Patients with Autoimmune Hepatitis Features.
Wen M; Men R; Fan X; Shen Y; Ni P; Hu Z; Yang L
Dig Dis; 2021; 39(4):366-374. PubMed ID: 33238269
[TBL] [Abstract][Full Text] [Related]
15. Epidemiological trends and outcomes of primary biliary cholangitis in South Korea between 2009 and 2019.
Kim KA; Choi HY; Ki M; Jang ES; Jeong SH
J Gastroenterol; 2023 Jul; 58(7):682-692. PubMed ID: 37195516
[TBL] [Abstract][Full Text] [Related]
16. Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study.
Trivedi PJ; Lammers WJ; van Buuren HR; Parés A; Floreani A; Janssen HL; Invernizzi P; Battezzati PM; Ponsioen CY; Corpechot C; Poupon R; Mayo MJ; Burroughs AK; Nevens F; Mason AL; Kowdley KV; Lleo A; Caballeria L; Lindor KD; Hansen BE; Hirschfield GM;
Gut; 2016 Feb; 65(2):321-9. PubMed ID: 25567117
[TBL] [Abstract][Full Text] [Related]
17. Effects of Bezafibrate on Outcome and Pruritus in Primary Biliary Cholangitis With Suboptimal Ursodeoxycholic Acid Response.
Reig A; Sesé P; Parés A
Am J Gastroenterol; 2018 Jan; 113(1):49-55. PubMed ID: 29016567
[TBL] [Abstract][Full Text] [Related]
18. Molecular mechanisms of ursodeoxycholic acid toxicity & side effects: ursodeoxycholic acid freezes regeneration & induces hibernation mode.
Kotb MA
Int J Mol Sci; 2012; 13(7):8882-8914. PubMed ID: 22942741
[TBL] [Abstract][Full Text] [Related]
19. [Treatment of cholestatic liver diseases with ursodeoxycholic acid].
Boberg KM; Schrumpf E
Tidsskr Nor Laegeforen; 1997 Sep; 117(23):3370-3. PubMed ID: 9411890
[TBL] [Abstract][Full Text] [Related]
20. Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score.
Carbone M; Nardi A; Flack S; Carpino G; Varvaropoulou N; Gavrila C; Spicer A; Badrock J; Bernuzzi F; Cardinale V; Ainsworth HF; Heneghan MA; Thorburn D; Bathgate A; Jones R; Neuberger JM; Battezzati PM; Zuin M; Taylor-Robinson S; Donato MF; Kirby J; Mitchell-Thain R; Floreani A; Sampaziotis F; Muratori L; Alvaro D; Marzioni M; Miele L; Marra F; Giannini E; Gaudio E; Ronca V; Bonato G; Cristoferi L; Malinverno F; Gerussi A; Stocken DD; Cordell HJ; Hirschfield GM; Alexander GJ; Sandford RN; Jones DE; Invernizzi P; Mells GF;
Lancet Gastroenterol Hepatol; 2018 Sep; 3(9):626-634. PubMed ID: 30017646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
